BillionToOne is positioning itself not just as a diagnostics player, but as a category-defining healthcare company with disruptive technology and accelerating financial performance. Investors will be weighing the promise of its breakthrough platform and growing test adoption against the risks of operating in a highly competitive and capital-intensive diagnostics market.